University Heart - UMMC
Return to Locations Search
Address:
2500 N. State St.
Jackson, MS 39216
Contact Us:
(601) 984-1000
Parking:
Directions:
From North State Street, turn onto the main campus at the stoplight (across from Back Yard Burgers). Turn left and follow University Drive. Take your first right after Parking Garage A. University Heart is located at the end of the street.
Our Care Specialties at this location:
Our Clinical Trials offered at this location:
Researchers at UMMC are committed to discovering innovative ways to prevent and treat the diseases that affect our daily lives. Clinical research studies play a vital role in the advancement of medicine and can improve the well-being of our families, friends, communities, and future generations. In this way, participation in clinical research studies furthers our vision to create "a healthier Mississippi."
Partnering with UMMC’s researchers may have many advantages, including:
- Gaining access to investigational treatments
- Increasing knowledge about your own health
- Giving the gift of improved health to our communities and future generations
- Contributing to the advancement of science by helping researchers learn more about how the human body and mind work or by helping find a cure or better treatments for diseases
| Clinical Trials | Publish Date | Description | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
A multicenter, randomized, double-blind, parallel-group, placebo-controlled study to evaluate the efficacy and safety of finerenone on morbidity and mortality in participants with heart failure (NYHA II-IV) and left ventricular ejection fraction ≥ 40% (LVEF ≥ 40%)IRB Number: 2020V0284
Published: January 14, 2022
View Locations
Clinical Trial Locations:
|
20220114161531 |
<div>The purpose of this study is to look at how well the study drug, Finerenone, works in patients <span style="font-size: 1rem; color: #0a0a0a;">with heart failure, to learn if the study drug is safe for the patients and how it </span><span style="font-size: 1rem;">affects the body</span></div> heart health 20103 Theresa Hutson rlong Heart Health |
||||||||||||
A Multicenter, Randomized, Placebo Controlled Study to Evaluate the Safety and Efficacy of AT-001 in Patients with Diabetic Cardiomyopathy / Stage B Heart Failure at High Risk of Progression to Overt Heart Failure (Stage C Heart Failure)IRB Number: 2020V0166
Published: October 20, 2021
View Locations
Clinical Trial Locations:
|
20211020154932 |
To evaluate the efficacy of AT-001 compared with placebo in preventing death or
hospitalization due to cardiac events. cardiac;heart;heart health AT-001-2001 Theresa Hickey lpapadimitriou Heart Health |
||||||||||||
A Randomized, Open-label Study of Dapagliflozin in Patients with Type 2 Diabetes Admitted with Acute Heart FailureIRB Number: 2020-0133
Published: January 11, 2022
View Locations
Clinical Trial Locations:
|
20220111163702 |
This study is for patients with Type II diabetes and who have come to the hospital with symptoms of Acute Heart Failure (AHF). It is designed to compare usual care to using dapagliflozin along with the usual care to treat AHF in hospitalized patients. Dapagliflozin is an FDA approved medication that is already used to help patients manage Type II Diabetes. dictate-ahf;type 2 diabetes;heart health ESR-19-14538 Theresa Hutson Gabriel Hernandez Heart Health |
||||||||||||
ALgorithm using LINQ Sensors for EValuatIon And TreatmEnt of Heart Failure (ALLEVIATE-HF)IRB Number: 2020V0235
Published: December 21, 2020
View Locations
Clinical Trial Locations:
|
20201221154446 |
The purpose of the study is to gain experience with implementation of a
patient management pathway including protocolized PRN medication
interventions in subjects with a “high” heart failure risk status, which is
derived from an integrated device diagnostic-based risk stratification
algorithm based on data collected by the Reveal LINQ device. Additionally,
data collected in observational subjects will be utilized to estimate the
sensitivity and false detection rate of the heart failure risk status algorithm
for prediction of heart failure events cardiac;heart failure;heart health MDT19005 Connie Watson rlong Heart Health |
||||||||||||
ARTEMIS - Effects of Ziltivekimab Versus Placebo on Cardiovascular Outcomes in Patients With Acute Myocardial InfarctionIRB Number: 2024-298
Published: July 10, 2025
View Locations
Clinical Trial Locations:
|
20250710135758 |
<div>The research study is being done to see if ziltivekimab can be used to treat people who were admitted to hospital because of a heart attack. Ziltivekimab might reduce development of heart disease, thereby preventing new heart attacks or strokes. Participants will either get ziltivekimab (active medicine) or placebo (a dummy medicine which has no effect on the body). Which treatment participants get is decided by chance. The chance of getting ziltivekimab or placebo is the same. The participant will need to inject the study medicine into a flat skin surface in there stomach, thigh, or upper arm once every month. Ziltivekimab is not yet approved in any country or region in the world. It is a new medicine that doctors cannot prescribe. The study will last for about 2 years.</div><div><br></div> artemis;heart;heart disease;ziltivekimab;myocardial;myocardial infarction EX6018-4979 ARTEMIS Memrie Cochran alemor Heart Health |
||||||||||||
Dapagliflozin and Effect on Cardiovascular Events in Acute Heart Failure -Thrombolysis in Myocardial Infarction 68 (DAPA ACT HF-TIMI 68)IRB Number: 2020-0163
Published: January 12, 2022
View Locations
Clinical Trial Locations:
|
20220112141836 |
This study will test whether the drug dapagliflozin is safe and has beneficial effects when added
to conventional heart failure therapy in patients who have been admitted to the hospital for acute
heart failure and whose heart is not pumping enough blood with each heartbeat. D1699C00004 Theresa Hutson rlong Heart Health |
||||||||||||
LUX-DxTM Insertable Cardiac Monitor Remote Programming and Performance StudyIRB Number: 2021-1100
Published: March 21, 2022
View Locations
Clinical Trial Locations:
|
20220321184233 |
The purpose of this study is to collect information on how the LUX-Dx ICM system performs in patients who have different kinds of medical conditions that put them at risk for potentially harmful irregular or abnormal heart beats 2021v0744;heart health/cardiovascular C2045 Memrie Cochran jhamilton Heart Health |
||||||||||||
MK-1242-035: A Pivotal Phase 3 Randomized, Placebo-controlled Vericiguat Outcomes Study in HFrEF (VICTOR)IRB Number: 2021V0793
Published: March 02, 2022
View Locations
Clinical Trial Locations:
|
20220302112702 |
This study is testing MK-1242 (vericiguat) in people with a certain type of heart failure. It will compare MK-1242 to placebo (inactive substance) when added to your existing heart failure treatment. You, your study doctor and the study staff won't know what study drug you are getting. MK-1242 is experimental. heart health;victor;mk-1242 MK-1242-035 Will Pierce lpapadimitriou Heart Health |
||||||||||||
Pragmatic Evaluation of Events And Benefits of Lipid-lowering in older Adults (PREVENTABLE)IRB Number: 2020V0312
Published: January 15, 2021
View Locations
Clinical Trial Locations:
|
20210115100959 |
<span style="color: #000000; font-family: &quot;Source Sans Pro&quot;, &quot;Helvetica Neue&quot;, Helvetica, Roboto, Arial, sans-serif; font-size: 14px; background-color: #ffffff;">PREVENTABLE is a multi-center, randomized, parallel group, placebo-controlled superiority study. Participants will be randomized 1:1 to atorvastatin 40 mg or placebo. This large study conducted in community-dwelling older adults without cardiovascular disease (CVD) or dementia will demonstrate the benefit of statins for reducing the primary composite of death, dementia, and persistent disability and secondary composites including mild cognitive impairment (MCI) and cardiovascular events.</span><div><span style="color: #000000; font-family: &quot;Source Sans Pro&quot;, &quot;Helvetica Neue&quot;, Helvetica, Roboto, Arial, sans-serif; font-size: 14px; background-color: #ffffff;"><br></span></div> cardiac;heart;men's health;women's health;obesity;nutrition PREVENTABLE Theresa Hutson mehall Heart Health Women's Health |
||||||||||||
Prospective comparison of ARNI with ARB Given following stabiLization In DEcompensated HFpEF (PARAGLIDE-HF)IRB Number: 2020-2778
Published: January 12, 2022
View Locations
Clinical Trial Locations:
|
20220112135215 |
The purpose of this research study is to find out if the study drug, sacubitril/valsartan, is safe and has beneficial effects when added to conventional heart failure therapy in patients with heart failure with preserved ejection fraction who have been stabilized after being admitted to the hospital for new or worsening heart failure. CLCZ696DUS01 Theresa Hutson rlong Heart Health |